Vaccine Development

Recombinant BCG May Have Host of Uses

Published in Gene Therapy Weekly, September 8th, 1997

Immune responses to an antigen delivered by recombinant bacillus Calmette-Guerin are under complex genetic influences which could play a crucial role in the efficiency of future recombinant BCG vaccines.

Bacillus Calmette-Guerin (BCG) has been used in more than 3 billion people for protection against Mycobacterium tuberculosis, with a very low incidence of serious side effects. Recently, the development of integrative and extrachromosomal expression vectors has enabled cloning and expression of foreign genes in BCG (Aldovini et al., Nature 1991;351:479-482). A variety of viral, bacterial, and parasitic antigens have been expressed successfully in BCG. In...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry